Frontiers in Nutrition
August 21, 2025
Jakub Słupski, Agnieszka Mechlińska, Adam Włodarczyk et al.
1 citation
Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BP), significantly impact global health, with MDD affecting over 300 million people and BP affecting approximately 2% of the world's population. Ketamine, originally an anesthetic, has emerged as a promising treatment for patients with treatment-resistant depression (TRD), due to its unique pharmacological...
Neuropharmacology
August 21, 2025
James J Gattuso, Geraldine Kong, Bilgenur Bezcioglu et al.
7 citations
Psilocybin, a serotonergic compound that produces psychedelic effects primarily through activation of the 5-HT2A receptor, has shown promise in treating neuropsychiatric conditions, including obsessive-compulsive disorder (OCD). However, the effects of chronic psilocybin administration on gut function, microbiota, and behavioural phenotypes remain understudied. The present study investigated...
Psychiatry Research
August 20, 2025
L. Mcinnes, Robert M. Berman, Matthew J Worley et al.
OBJECTIVE The study evaluated the effectiveness of Ketamine Intravenous Therapy (KIT) in reducing post-traumatic stress disorder (PTSD) and depression symptoms, using electronic health record data from outpatient psychiatric patients with PTSD. METHOD We analyzed data from 8,136 patients diagnosed with PTSD, 87 % (N = 7,070) of whom also had comorbid depression. Symptom severity was measured...
PsyArXiv
August 20, 2025
Deepanshu Tomar
preprint
The Bi-Interpretive Mind Framework (BIMF) introduces a dual-system model of human cognition and consciousness, positing the coexistence of two interdependent subsystems: the Primary Mind (logical, conscious, reality-testing) and the Secondary Mind (intuitive, unconscious, biologically interpretive). Subjective experience is conceptualized as emerging from the “interpretive handshake” between...
International Journal of Advanced Research in Science, Communication and Technology
August 20, 2025
Ayushi Deora
Background: The interplay of spirituality and medicine in Buddhist India can be used as a paradigm platform that has been guiding the healing activities more than 2000 years. Understanding the ancient Ayurveda and combining it with Buddhism spiritual values have been the study of this research work toward their applicability in the contemporary field of healthcare. Aim: Examine the history of...
Psychoactives
August 20, 2025
Tayler Holborn, Fabrizio Schifano, Emma E Smith et al.
1 citation
Numerous individuals suffer from mental health issues including depression and anxiety, resulting in substantial societal burden. Data suggests individuals are choosing to self-medicate with Novel Psychoactive Substances (NPS); however, this phenomenon is poorly understood. We aimed to investigate which NPS are being used to self-medicate, evaluate their perceived effectiveness and examine...
Expert Opinion on Drug Metabolism & Toxicology
August 19, 2025
Alice Caulfield, Elliot Hampsey, Allan H. Young
1. Classical psychedelics are gaining attention as potential treatments for a range of neuropsychiatric conditions, including depression, anxiety, and addictions [1]. Psychedelics differ from tradi...
The International Journal of Neuropsychopharmacology
August 18, 2025
Pierre Blier, Mostafa El Mansari
Abstract Background Low dose ketamine has been shown, in animal studies, to enhance firing activity of norepinephrine neurons in the locus coeruleus, and burst as well as population activity of dopamine neurons in the ventral tegmental area [1]. These brainstem monoamine nuclei densely innervate the PFC, where clinical studies have shown a facilitation of glutamatergic neurotransmission in the...
The International Journal of Neuropsychopharmacology
August 18, 2025
S Rossell
Abstract Background There has been a surge of interest in psychedelic research, especially with regards to the therapeutic properties of these compounds. This has led to the emergence of psychedelic assisted psychotherapy (PAP). PAP is showing promise for a range of mental health conditions, including major depressive disorder and PTSD, leading to (perhaps premature) international changes in...
ACS Medicinal Chemistry Letters
August 15, 2025
Robert B. Kargbo
Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syndromes. Structural modifications yield functional selectivity at 5-HT receptors, mitigating hallucinogenic risk while preserving therapeutic efficacy. This study integrates receptor and behavioral data to support phenalkylamines and psilocybin as...